ArticleBMJ open2026
Transcutaneous vagus nerve stimulation as add-on therapy versus pharmacotherapy alone (TRAVAST): study protocol for a prospective, randomised, triple-blind, controlled, multicentre trial.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDespite optimised antiseizure medication, pharmacoresistant epilepsy still affects a substantial proportion of adult patients, especially when epilepsy surgery is not possible or is rejected. Transcutaneous vagus nerve stimulation (t-VNS) is a non-invasive neuromodulatory approach for which the evidence from randomised studies to date does not allow for a reliable assessment of its benefits due to small case numbers and methodological limitations. Transcutaneous vagus nerve stimulation as add-on therapy versus pharmacotherapy alone (TRAVAST) is a prospective, multicentre, randomised, triple-blind, controlled trial to investigate whether t-VNS as an add-on to established pharmacotherapy improves seizure-related and patient-relevant outcomes in adults with pharmacoresistant epilepsy. METHODS AND ANALYSIS: A total of 164 adults (aged 18-65) with pharmacoresistant epilepsy and clinically manifest seizures who are not eligible for or refuse (further) resective epilepsy surgery will be enrolled at 15 sites. Patients are assigned 1:1 to active t-VNS or sham stimulation in addition to stable antiseizure medication for 12 months. t-VNS is performed using a non-implanted stimulator with an ear electrode as a daily self-administered therapy in the home environment. The primary outcome is the proportion of patients with at least 50% reduction in mean seizure frequency after 52±2 weeks compared with a 4-week baseline period, documented in a standardised epilepsy diary. Secondary outcomes include additional response rates, seizure freedom, seizure severity, health-related quality of life, psychological and cognitive parameters, treatment retention and safety, including device-related events and sudden unexpected death in epilepsy. ETHICS AND DISSEMINATION: The trial protocol has been approved by an ethics committee (Ethics Committee of LMU of Munich). All patients will provide written consent prior to inclusion and can withdraw from the trial at any time without this affecting their further care. The results will be published in specialist journals, reported in trial registries, made available anonymously for scientific use and communicated back to the participating physicians, patients and the public. TRIAL REGISTRATION NUMBER: DRKS00039592.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.